Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications Median time to relapse was 7.4 ...
Multiple myeloma care shifts to four-drug frontline regimens and MRD testing, boosting deep responses and guiding relapse ...
Standardization of 18F-FDG–PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma We analyzed patients with relapse after ES-HL treated ...
Ace the Case: First Relapse After Quadruplet Therapy: CAR T Selection, Bridging, and Toxicity Timing
Previously reserved for heavily pretreated patients in the late stages of relapse, CAR T-cell therapy is now regarded as an effective option for achieving deep, durable responses in some patients with ...
Nearly everyone with multiple myeloma relapses. That doesn’t make it easy. A cancer diagnosis is traumatic, especially when the cancer is treatable, but not curable. In multiple myeloma, the disease ...
Fred D. Lublin, MD, discusses evolving concepts in MS, including earlier high-efficacy therapy, unrecognized progression, and ...
For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results